Pfizer, Inc. vs Zimmer Biomet Holdings, Inc. — Stock Comparison
Pfizer, Inc. (PFE) and Zimmer Biomet Holdings, Inc. (ZBH) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Zimmer Biomet Holdings, Inc. narrowly edges Pfizer, Inc. on Q·Score (7 vs 6.4 out of 10), led by Growth (8.8 vs 5.1) and Health (7.6 vs 7). Pfizer, Inc. scores higher on Valuation, reflecting stronger P/E and price-target positioning. Analyst consensus targets imply greater upside for PFE (+15.8%) than for ZBH (+12.2%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Forward P/E of 8.9× is low relative to sector peers.
⚠ earnings contracting 10% year-over-year.
Earnings growing 34% year-over-year on 9% revenue growth.
⚠ cautious analyst consensus — few Buy ratings.
Analyst Consensus
Fundamentals
Frequently Asked Questions
PFE vs ZBH: which stock scores better overall?
Based on Q·Score, Zimmer Biomet Holdings, Inc. (ZBH) scores 7/10 versus Pfizer, Inc. (PFE) at 6.4/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: PFE or ZBH?
Zimmer Biomet Holdings, Inc. (ZBH) scores higher on Growth (8.8/10 vs 5.1/10). Pfizer, Inc. reports revenue growth (5.4% YoY) while Zimmer Biomet Holdings, Inc. reports (9.3% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is PFE or ZBH more attractively valued?
Pfizer, Inc. (PFE) scores higher on Valuation (7.7/10 vs 7.2/10). PFE trades at 8.9× P/E versus ZBH at 9.8×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about PFE vs ZBH?
There are 27 analysts covering PFE with a consensus price target of $29.19, and 20 analysts covering ZBH with a consensus target of $98.70. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: PFE or ZBH?
Pfizer, Inc. (PFE) scores higher on Quality (6.4/10 vs 6/10). Net profit margin: PFE at 11.8%, ZBH at 9.1%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: PFE or ZBH?
Zimmer Biomet Holdings, Inc. (ZBH) scores higher on Financial Health (7.6/10 vs 7/10). Market beta: PFE at 0.29, ZBH at 0.47. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of PFE and ZBH?
Pfizer, Inc. (PFE) has a market capitalisation of $143.7B, while Zimmer Biomet Holdings, Inc. (ZBH) has a market cap of $17.0B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do PFE or ZBH pay dividends?
PFE pays a dividend yield of 6.61%, while ZBH pays a dividend yield of 1.07%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →